LAM KID

[Osteoporotic patient’s use of prescription drugs - pilot study]

BATKA Gábor1, SZENTANDRÁSSY Andrea Éva2, SZEKERES László2

OCTOBER 20, 2011

LAM KID - 2011;1(02)

[BACKGROUND - In Hungary, the number of the highest mortality hip fractures is between 12 000-15 000 per year. The cost of treating hip fractures is several times higher than that of preventive medical therapy. Thus, the compliance of patients with osteoporosis is of great importance. METHODS - Using the informatical database of St. András Rheumatology Hospital at Héviz, we collected one year’s prescription drugs for osteoporosis and compared them with the number of drugs obtained by the patients, determined from National Health Insurance data. RESULTS - In general, the patients obtained 75% of prescription drugs. From the 4354 boxes of prescribed antiporotics, 3637 contained bisphosphonate (not considering vitamin D and calcium). Within this group, 88% of combination preparations were obtained, which is a greater ratio than that of non-combination bisphosphonates (84%). CONCLUSIONS - On the basis of our results, we posit that prescription of a combination preparation somewhat improves the patients’ compliance. The low concordance of vitamin D and calcium preparations is worrying.]

AFFILIATIONS

  1. Zala Megyei Kórház
  2. Hévízgyógyfürdô és Szent András Reumakórház Nonprofit Kft.

COMMENTS

0 comments

Further articles in this publication

LAM KID

[Connections of bone turnover and energy homeostasis in women]

BUDAY BARBARA, PACH Péter, LITERÁTI-NAGY Botond, VECSEI Zsuzsa, KORÁNYI LÁSZLÓ

[BACKGROUND - A new discovery of the past decade has been the previously unknown relationship between the bone metabolic unit and energy homeostasis. On the basis of data from previous animal and clinical studies, osteocalcin has been considered the major mediator of this relationship. Cathepsin K is a cysteine protease type osteolytic enzyme, which has a role in bone resorption, and which is a pharmaceutical target in the treatment of osteoporosis and bone metastasis. According to data from animal studies, its deficiency or selective inhibition decreases the differentiation of preadipocytes, body weight and serum levels of insulin and glucose in obese mice. The aim of our study was to elucidate the role of cathepsin K in the human bone - metabolic axis in women (n=66). PATIENTS AND METHODS - 21 healthy and 45 glucose intolerant women were examined. OGTT, IVGTT and hyperinsulinaemic euglycaemic clamp were performed to assess carbohydrate homeostasis, insulin secretion, whole-body and muscle glucose utilization (M-1 and M-3). Circulating levels of bone markers and adipokines were measured, and DEXA was used to measure BMD, fat and muscle mass. RESULTS - Cathepsin K levels showed a significant (p<0.05), negative correlation with BMI, body fat percent and OGTT glucose and insulin area under the curve (AUC), and a positive correlation with M values. No correlation was found between cathepsin K levels and IVGTT measurements. CONCLUSION - Cathepsin K - in women - is not only a participant of the bone metabolism - energy homeostasis axis. Its role in human glucose homeostasis differs from what could be expected on the basis of animal experiments, because increasing cathepsin K levels indicate, paradoxically, improving metabolic state in women. Our data suggest that insulin regulation of cathepsin K is mediated by the incretin system.]

LAM KID

[A successful story of the science of bone metabolism in Hungary - Interview with István Marton, a founder of Hungarian Society of Osteoporosis and Osteoarthrology]

SZEKERES László

LAM KID

[Inhibition of receptor activator of nuclear kappa-B ligand: pathophysiology and preclinical data]

LAKATOS Péter, NÁDASI Edit

[Bone remodeling is a lifelong process, in which the balanced functions of osteoclasts and osteoblasts have a key role. In certain conditions, for example during the dramatical hormonal changes in the postmenopausal period, the upset of this balance leads to a pathologically increased bone loss. Such conditions lead to an increased bone loss, which results in an increased risk of fractures. Bone resorption is primarily regulated by a member of the tumor necrosis factor family, receptor activator of nuclear factor κB ligand, which plays a central role in the development, function and survival of osteoclasts. Catabolic effects of this ligand is inhibited by another member of the tumor necrosis factor family, osteoprotegerin, which binds to the ligand and prevents its interaction with its receptor, the receptor activator of nuclear factor κB. Osteoclast activity is at least partly dependent on the relative balance of the ligand and osteoprotegerin. It has been shown in a number of animal models that inhibition of the ligand markedly decreases bone resorption and increases cortical and cancellous bone volume, density and strength, without having any significant effect on other organs. On the basis of these findings, inhibition of receptor activator of nuclear κB ligand is a promising therapy of conditions characterised by increased bone loss. In phase 3 clinical trials, denosumab therapy significantly increased bone mineral density at various regions of the skeleton and significantly decreased the levels of bone turnover markers compared with placebo and alendronate therapy, and significantly decreased the incidence of new vertebral, total hip and nonvertebral fractures compared with placebo. On the basis of these findings, denosumab therapy offers a novel, revolutionary solution for the treatment of postmenopausal osteoporosis.]

LAM KID

[Pain relief in the neurologist’s view]

KOMOLY Sámuel

[Pain, on the basis of its anatomical origin, can be nociceptive (somatic, visceral) or neuropathic, that is, occuring as a direct consequence of a lesion or disease affecting the somatosensory system. The past few years’ epidemiological studies showed that chronic neuropathic pain affects 7-8% of the general population. Diagnosis of neuropathic pain can be established without instrumental examinations, with the help of validated tests that can be used by any physician. Neuropathic pain greatly deteriorates the patients’ quality of life, and the effect of traditional analgesics is insufficient for its treatment. Thus, it is important to know those treatment procedures and drugs that have been proved to be efficient for relieving neuropathic pain.]

LAM KID

[Osteoid osteoma]

MAGYAR Péter, KOVÁCS Balázs

All articles in the issue

Related contents

LAM Extra for General Practicioners

[SECONDARY OSTEOPOROSIS IN GASTROINTESTINAL DISEASES]

FUSZEK Péter

[Gastrointestinal disease is often overlooked or simply forgotten as a cause of osteoporosis. In a number of gastrointestinal diseases, sometimes because of the medicines used for their treatment, malabsorption syndrome may occur. Malabsorption might lead to insufficient absorption of calcium, phosphate, magnesium, vitamin D, vitamin K and proteins, which can cause osteopenia, osteoporosis and osteomalacia. In this paper, we aim to review the gastroenterological diseases that can lead to osteoporosis and treatment strategies.]

LAM Extra for General Practicioners

[DOES THE VITAMIN K2 PLAY A ROLE IN THE PREVENTION OR TREATMENT OF OSTEOPOROSIS? - A SYSTEMATIC REVIEW]

SZILI Balázs, TAKÁCS István

[The physiological role of vitamin K in blood clotting and bone metabolism is well known. A number of articles have been published recently about the effects of vitamin K2 on bone. Non-professional media promotes vitamin K2 as a potent tool for the prevention and treatment of osteoporosis. Nevertheless vitamin K2 is not included in either Hungarian, or European, or Ameri - can guidelines as an anti-osteoporotic me - dication. Our aim was to review the literature and provide a systematic review on the role of vitamin K2 in the prevention and treatment of osteoporosis. We have searched articles on http://pubmed. org available on 14. February 2014. Our search terms were: („ vitamin K2” OR „ menaquinon” OR „ MK-7” OR „ menantrenon”) AND „ osteoporosis”. We have only reviewed original articles that discussed the relationship of vitamin K2 and osteoporosis, and had at least the abstract available in English. Of the 155 articles found, 135 had a relevant topic, 126 had at least the abstract in English. Of these, 73 were original articles, including 44 human studies (8 doubleblind, controlled, 26 open-label, controlled, 5 observational and 5 cross-sectional studies) and 29 animal or in vitro models. In the non-Asian population there is no evidence for fracture-preventing or BMD-increasing effect of vitamin K2 treatment. The currently recommended anti-osteoporotic medications are significantly more efficient compared with the BMD increase observed in some Asian studies.]

LAM Extra for General Practicioners

[THE IMPORTANCE OF VITAMIN D DEFICIENCY IN PRACTICE]

TAKÁCS István

[The effects of vitamin D in bone health have been known since the 1920s. Recently, it has been proven that its role in the body is much more complex. Activated vitamin D is a steroid hormone that regulates transcription of more than 200 human genes through its receptor that is detectable in almost all types of cells. In contrast to the former conceptions, it can be activated not only in the kidneys; moreover, local 1-α-hydroxylation plays a greater role in its extraskeletal effects. Vitamin D deficiency, currently defined as serum levels of <30 ng/ml, is caused by the lack of ‘effective’ sunlight exposition. Thus, vitamin D deficiency is one of the most frequent deficiencies in the developed world that plays a role not only in the development of skeletal conditions but many other diseases, as well. A low vitamin D level causes a reduced calcium absorption, a higher bone remodelling rate and increased bone loss. It also reduces muscle strength and increases the risk of falling. Normal vitamin D status is required for the effectiveness of drugs for osteoporosis treatment; however vitamin D treatment in itself is not effective in osteoporosis. An increasing number of studies show the benefits of vitamin D supplementation and treatment in extraskeletal conditions. Vitamin D plays an important role in the prevention of several auto-immune diseases, infections, cardiovascular diseases, and cancers. Therefore, all UV-B radiation-deprived adults require an intake of vitamin D to maintain a level of >30 ng/ml. Vitamin D3 treatment is safe. The necessary dose can be reliably approximated by the calculation that an incremental consumption of 100 IU/day raises serum vitamin levels by 1,0 ng/ml. Clinical trials suggest that for the vast majority of individuals, a prolonged intake of 10,000 IU/day does not pose any risk.]

LAM KID

[The role of bone turnover markers in the diagnosis and therapy of osteoporosis]

HONTVÁRI Lívia, KRÁNICZ Ágota

[Osteoporosis is a metabolic bone diseasecharacterised by decreased bone mass andimpaired bone turnover, which leads to anincreased risk of fractures and significantmorbidity and mortality. Its social and pub-lic health impact and the importance of itsearly and accurate diagnosis are indis-putable. The aim of timely and efficienttherapy is to improve bone quality as wellas to prevent the dreaded complications ofbone fractures. In clinical practice, labora-tory diagnosis of biochemical bone mark-ers are particularly important for therapeu-tic monitoring. In this article, reviewing lit-erature data, we discuss bone-specificmarkers from the clinician’s perspective,and highlight their importance in everydayclinical practice. ]

Lege Artis Medicinae

[BISPHOSPHONATES IN THE TREATMENT OF BONE METASTASES]

NAGYKÁLNAI Tamás

[Bisphosphonates are used in the treatment of malignant diseases with bone metastases and of osteoporosis. The currently available bisphosphonates have a wide range of effectiveness, tolerability and dosing profiles. In metastatic disease, bisphosphonate therapy is aimed at the correction of hypercalcaemia and the reduction of skeletal-related events due to malignancy metastatic to bone. Large clinical trials have shown that long-term administration of bisphosphonates can reduce skeletal-related events by 30 to 40% and significant analgesic effect is reached in at least 50% of the patients. The superiority of zoledronate to the old standard pamidronate has been proved in large randomized trials. Despite the fact that bisphosphonates are generally well tolerated, certain toxicities such as renal toxicity and osteonecrosis of the jaw should be considered with prolonged use.]